A series of conformationally restricted benzopyran based triarylethylenes has been synthesized and characterized as potential growth inhibitors of breast carcinoma cells. The synthesized compounds (14a–b, 15a and 16a–e) presented significant growth inhibition of ER+ and ER− breast cancer cells within the range of IC50 0.55–9.96 µM. Amongst other, 16c showed potent anticancer activity at IC50 0.95 µM